Form 4: Aptevo Therapeutics SVP, CFO Daphne Taylor Reports Stock Transactions

Daphne Taylor, SVP and CFO of Aptevo Therapeutics, reports transactions involving restricted stock units converting into common stock.

Summary

• Daphne Taylor, the SVP and CFO of Aptevo Therapeutics Inc., filed a Form 4 detailing changes in beneficial ownership.
• The report covers transactions involving restricted stock units (RSUs) that convert into common stock on a one-for-one basis.
• On March 2, 2025, Taylor converted 2 RSUs into 2 shares of common stock.
• On March 4, 2025, Taylor converted 1 RSU into 1 share of common stock.
• The RSUs converted on March 2, 2025, are part of a grant of 11,000 (7 post-splits) RSUs from March 3, 2023, vesting in three annual installments starting March 2, 2024.
• The RSUs converted on March 4, 2025, are part of a grant of 4,750 (3 post-splits) RSUs from June 7, 2022, vesting in three annual installments starting March 4, 2023.

Sentiment

Score: 5

Explanation: This is a routine filing related to stock transactions by an officer, and doesn't inherently indicate positive or negative sentiment.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. These filings are closely watched by investors seeking insights into management's perspective on the company's stock.

Stakeholder Impact

• The transactions may have a minor dilutive effect on existing shareholders due to the issuance of new shares.

Key Dates